961PRisk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance. (23rd October 2018) - Thein, K Z; Sultan, A; Zaw, M H; Han, M M; Yendala, R; Zin, M M; Awasthi, S; D'Cunha, N; Hardwicke, F; Jones, C